Anne Sempowski Ward
Known title: DirectorCIK: 0001790117
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Stifel Keeps Hold Rating on SPS Commerce, Up Target to $85. Stifel has kept its hold rating on SPS Commerce while lifting its price target to $85. The new target sits above the current consensus average of $75.45 and near the top of the 52‑week range. The rating suggests the brokerage sees no immediate upside or downside. The stock is trading with an RSI of 57.3 and a revenue‑price divergence signal over the past year.
Transaction History
| VNDA | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 | View on chart |
| SPSC | ▲ Buy | Grant | 3,736 | $0 | 5/28/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 | View on chart |
| SPSC | ▲ Buy | Grant | 1,310 | $0 | 5/13/2025 | View on chart |
| VNDA | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 | View on chart |
| SPSC | ▲ Buy | Grant | 465 | $0 | 5/16/2024 | View on chart |
| VNDA | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 | View on chart |
| SPSC | ▲ Buy | Grant | 585 | $0 | 5/12/2023 | View on chart |
| VNDA | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 | View on chart |
| SPSC | ▲ Buy | Grant | 838 | $0 | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.